The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival

[1]  C. Hassan,et al.  Interobserver agreement and accuracy of preoperative endoscopic ultrasound-guided biopsy for histological grading of pancreatic cancer , 2014, Endoscopy.

[2]  N. Petrucciani,et al.  Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph nodes. , 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[3]  Stephen A. Sastra,et al.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.

[4]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[5]  F. Bendtsen,et al.  Mortality, cancer, and comorbidities associated with chronic pancreatitis: a Danish nationwide matched-cohort study. , 2014, Gastroenterology.

[6]  Mauro Ferrari,et al.  Transport properties of pancreatic cancer describe gemcitabine delivery and response. , 2014, The Journal of clinical investigation.

[7]  N. Luheshi,et al.  Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists , 2014, Oncoimmunology.

[8]  Jeffrey E. Lee,et al.  Pancreatic intraepithelial neoplasia and histological changes in non‐neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma , 2013, Histopathology.

[9]  H. Einsele,et al.  Tumor Necrosis Factor Induces Tumor Promoting and Anti-Tumoral Effects on Pancreatic Cancer via TNFR1 , 2013, PloS one.

[10]  W. Frankel,et al.  Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. , 2013, Cancer research.

[11]  F. Di Maggio,et al.  Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes , 2013, The Journal of pathology.

[12]  W. Greenhalf,et al.  New biomarkers and targets in pancreatic cancer and their application to treatment , 2012, Nature Reviews Gastroenterology &Hepatology.

[13]  R. Gillies,et al.  Evolutionary dynamics of carcinogenesis and why targeted therapy does not work , 2012, Nature Reviews Cancer.

[14]  D. Bar-Sagi,et al.  Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. , 2012, Cancer cell.

[15]  Matthew J. Craig,et al.  IL‐4 induces proliferation in prostate cancer PC3 cells under nutrient‐depletion stress through the activation of the JNK‐pathway and survivin up‐regulation , 2012, Journal of cellular biochemistry.

[16]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Andersson,et al.  Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer , 2011, The British journal of surgery.

[18]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[19]  C. Tudur-Smith,et al.  Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer , 2011, British Journal of Cancer.

[20]  N. Jamieson,et al.  Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis , 2011, Clinical Cancer Research.

[21]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[22]  Douglas B. Evans,et al.  Secreted Interleukin-1α Induces a Metastatic Phenotype in Pancreatic Cancer by Sustaining a Constitutive Activation of Nuclear Factor-κB , 2009, Molecular Cancer Research.

[23]  Y. Meng,et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.

[24]  M. Ychou,et al.  Histopathological Response to Preoperative Chemoradiation for Resectable Pancreatic Adenocarcinoma: The French Phase II FFCD 9704-SFRO Trial , 2008, American journal of clinical oncology.

[25]  David Goldstein,et al.  Pancreatic stellate cells: partners in crime with pancreatic cancer cells. , 2008, Cancer research.

[26]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Iacobuzio-Donahue,et al.  Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[29]  M. Pirisi,et al.  Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival , 2006, Cancer Immunology, Immunotherapy.

[30]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[31]  S. Leach,et al.  Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates , 2005, Development.

[32]  T. Baba,et al.  Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-α transduction , 2005, Gene Therapy.

[33]  E. Paulson,et al.  Significance of Histological Response to Preoperative Chemoradiotherapy for Pancreatic Cancer , 2005, Annals of Surgical Oncology.

[34]  M. Kornmann,et al.  Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions , 2005, British Journal of Cancer.

[35]  B. Sipos,et al.  Tumor Stroma Interactions Induce Chemoresistance in Pancreatic Ductal Carcinoma Cells Involving Increased Secretion and Paracrine Effects of Nitric Oxide and Interleukin-1β , 2004, Cancer Research.

[36]  T. Oshikiri,et al.  CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.

[37]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[38]  K. Xie,et al.  Interleukin-8 and human cancer biology. , 2001, Cytokine & growth factor reviews.

[39]  T. Gress,et al.  TGF‐β–induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase‐2 and the urokinase plasminogen activator system , 2001, International journal of cancer.

[40]  M. Imamura,et al.  Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cells. , 2001, Anticancer research.

[41]  Hiroshi Takamori,et al.  Autocrine Growth Effect of IL-8 and GRO&agr; on a Human Pancreatic Cancer Cell Line, Capan-1 , 2000, Pancreas.

[42]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[43]  Masato Kato,et al.  Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2 , 1998, Nature Medicine.

[44]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  F. Ames,et al.  Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1992, Archives of surgery.

[46]  C. Yeo,et al.  Safety of perioperative aspirin therapy in pancreatic operations. , 2014, Surgery.

[47]  H. Friess,et al.  The role of inflammation in pancreatic cancer. , 2014, Advances in experimental medicine and biology.

[48]  A. Gao,et al.  Interleukin‐4 stimulates androgen‐independent growth in LNCaP human prostate cancer cells , 2008, The Prostate.

[49]  M. Karin.  Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[50]  M. Plebani,et al.  Pancreatic cancer cells invasiveness is mainly affected by interleukin-1beta not by transforming growth factor-beta1. , 2005, The International journal of biological markers.

[51]  Jeffrey E. Lee,et al.  Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration , 2022 .